4:47 PM
 | 
Jun 03, 2014
 |  BC Extra  |  Company News

CMS could save $18B by switching to Avastin from Lucentis

Medicare Part B could save $18 billion over 10 years if all patients were to receive Avastin bevacizumab instead of Lucentis ranibizumab to treat neovascular age-related macular degeneration (AMD) or diabetic macular edema (DME), according to an University of Michigan. The analysis, published in Health Affairs, estimates additional savings of $5 billion for patients and $6 billion in...

Read the full 290 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >